Cytokinetics (CYTK) Expected to Announce Earnings on Tuesday

Cytokinetics (NASDAQ:CYTK) is expected to issue its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect the company to announce earnings of ($1.48) per share and revenue of $8.0230 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Cytokinetics Price Performance

NASDAQ CYTK opened at $66.26 on Tuesday. The stock’s 50 day simple moving average is $63.39 and its 200 day simple moving average is $56.96. Cytokinetics has a one year low of $29.31 and a one year high of $70.98. The firm has a market cap of $8.10 billion, a PE ratio of -10.53 and a beta of 0.54.

Insider Buying and Selling at Cytokinetics

In related news, EVP Fady Ibraham Malik sold 2,200 shares of Cytokinetics stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $61.24, for a total transaction of $134,728.00. Following the completion of the sale, the executive vice president directly owned 138,552 shares of the company’s stock, valued at $8,484,924.48. The trade was a 1.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Andrew Callos sold 15,000 shares of the stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $61.93, for a total value of $928,950.00. Following the completion of the transaction, the executive vice president directly owned 50,440 shares in the company, valued at $3,123,749.20. The trade was a 22.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 156,385 shares of company stock worth $10,140,808. Insiders own 3.40% of the company’s stock.

Institutional Investors Weigh In On Cytokinetics

Hedge funds have recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new position in shares of Cytokinetics in the 4th quarter valued at $29,000. Northwestern Mutual Wealth Management Co. lifted its holdings in Cytokinetics by 46.0% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 171 shares in the last quarter. Quarry LP acquired a new position in Cytokinetics in the third quarter valued at about $30,000. Advisory Services Network LLC bought a new stake in shares of Cytokinetics in the third quarter worth about $32,000. Finally, Johnson Financial Group Inc. acquired a new stake in shares of Cytokinetics during the third quarter worth about $40,000.

Analysts Set New Price Targets

CYTK has been the topic of several research analyst reports. Leerink Partners set a $83.00 target price on Cytokinetics in a report on Monday, December 22nd. JPMorgan Chase & Co. raised their price objective on shares of Cytokinetics from $70.00 to $74.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Royal Bank Of Canada reiterated an “outperform” rating and set a $95.00 target price on shares of Cytokinetics in a research report on Wednesday, January 21st. The Goldman Sachs Group set a $95.00 price target on shares of Cytokinetics and gave the company a “buy” rating in a report on Thursday, December 18th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cytokinetics in a report on Tuesday, October 21st. Seventeen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.42.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.